year
loui
pasteur
show
chicken
protect
avian
cholera
inocul
attenu
cultur
germ
respons
diseas
pasteur
jule
charl
richet
found
protect
immun
transfer
dog
serum
dog
immun
staphylococci
richet
emil
von
behr
kitasato
found
rabbit
protect
lethal
dose
diphtheria
tetanu
toxin
inject
serum
rabbit
immun
toxin
behr
kitasato
von
behr
award
first
nobel
prize
medicin
physiolog
work
serotherapi
year
board
yacht
princ
albert
monaco
charl
richet
paul
portier
discov
anaphylaxi
immun
dog
minut
amount
toxin
sea
anemon
publish
provoc
find
richet
portier
five
year
later
richet
show
anaphylact
hypersensit
transfer
dog
serum
immun
dog
richet
richet
award
nobel
prize
medicin
physiolog
work
anaphylaxi
therefor
scientist
demonstr
immun
serum
either
protect
kill
recipi
challeng
deadli
pathogen
harmless
dose
toxin
respect
one
centuri
later
know
antibodi
respons
effect
immun
serum
antibodi
immunoglobulin
present
milligram
per
millilit
serum
antibodi
abund
effector
molecul
adapt
immun
respons
best
worst
antibodi
inde
protect
infecti
diseas
account
longterm
protect
confer
vaccin
increasingli
use
passiv
immunotherapi
antibodi
also
respons
diseas
includ
allergi
hemolyt
anemia
newborn
sever
autoimmun
diseas
antibodi
exert
protect
pathogen
effect
one
reason
antibodi
exert
biolog
effect
antibodi
specif
bind
antigen
therebi
gener
immun
complex
bind
noth
littl
antigen
inde
found
recent
neutral
virus
neutral
bacteri
toxin
long
paradigmat
exampl
biolog
properti
antibodi
due
mask
specif
site
antigen
requir
bind
requir
fc
portion
antibodi
depend
receptor
antibodi
joller
et
al
malleri
et
al
antibodi
affect
antigen
inde
need
bind
antigen
epitop
fab
portion
also
interact
fc
portion
effector
system
includ
solubl
molecul
compon
enzymat
cascad
complement
cell
express
receptor
fc
portion
antibodi
fcr
fcr
trigger
posit
neg
signal
signal
control
varieti
biolog
activ
given
cell
fcr
express
cell
mani
type
cell
express
variou
combin
fcr
fcrexpress
cell
differ
function
repertoir
antibodi
exert
wide
spectrum
biolog
activ
understand
antibodi
work
excit
endeavor
comprehend
complex
immun
respons
also
requir
aim
develop
new
vaccin
therapeut
antibodi
argu
fcr
uniqu
immunoreceptor
predetermin
specif
structur
signal
biolog
properti
actual
fcr
function
engag
immun
complex
cell
membran
build
multipl
superstructur
capabl
trigger
wide
function
repertoir
adapt
respons
multitud
antigen
stimuli
term
immunoreceptor
coin
follow
impass
discuss
meet
held
hungari
septemb
design
receptor
involv
antigen
recognit
possess
intracellular
tyrosinebas
activ
motif
term
immunoreceptor
rapidli
adopt
use
design
receptor
contain
immunoreceptor
tyrosinebas
activ
motif
itam
reth
cambier
also
receptor
contain
immunoreceptor
tyrosinebas
inhibit
motif
itim
soon
describ
et
al
immunoreceptor
loos
term
use
becam
even
looser
itim
found
innumer
molecul
evid
link
immun
et
al
sever
itam
one
itim
identifi
intracytoplasm
domain
fcr
promot
immunoreceptor
like
antigen
receptor
express
b
cell
bcr
antigen
receptor
express
cell
tcr
word
forg
concept
fcr
recogn
neither
nativ
antigen
bcr
associ
antigenderiv
peptid
major
histocompat
complex
molecul
express
antigenpres
cell
tcr
fcr
howev
recogn
antigenantibodi
complex
immun
complex
third
form
given
antigen
interact
deliv
signal
cell
immun
system
fcr
immunoreceptor
third
type
unlik
bcr
tcr
whose
express
restrict
b
lymphocyt
respect
fcr
wide
express
includ
cell
myeloid
lineag
unlik
lymphocyt
myeloid
cell
need
neither
prolifer
differenti
order
function
perform
varieti
biolog
process
abund
blood
stream
ubiquit
myeloid
cell
effector
innat
immun
equip
varieti
patternrecognit
receptor
molecul
wide
share
microorgan
antigen
receptor
fcr
howev
enabl
interact
specif
antigen
bind
fcr
antibodi
inde
endow
cell
bona
fide
antigen
receptor
fcr
antibodi
enrol
myeloid
cell
adapt
immun
respons
consequ
adapt
immun
use
effector
cell
innat
immun
unlik
bcr
tcr
contain
builtin
antigenspecif
subunit
fcr
antigenrecognit
structur
therefor
predetermin
antigen
specif
howev
adopt
antigen
specif
specif
provid
antibodi
bind
fcr
fig
fact
antigen
specif
dissoci
receptor
enabl
fcrexpress
cell
act
antigen
adapt
immun
system
confront
respond
product
antibodi
although
devoid
antigenrecognit
capabl
fcr
therefor
provid
myeloid
cell
whole
cognit
repertoir
b
cell
specif
individu
bcr
tcr
result
one
combin
variabl
gene
segment
among
mani
possibl
combin
form
b
cell
potenti
repertoir
specif
individu
fcr
subset
antibodi
b
cell
actual
repertoir
synthes
b
cellderiv
plasma
cell
happen
bind
fcr
specif
bcr
tcr
select
priori
potenti
combinatori
divers
gene
segment
wherea
fcr
select
posteriori
actual
divers
protein
unlik
b
cell
express
bcr
tcr
one
specif
fcrexpress
cell
carri
multipl
antibodi
differ
specif
antibodi
respons
inde
polyclon
gener
antibodi
sever
antigen
antibodi
one
antigen
direct
sever
epitop
antibodi
bind
fcr
irrespect
specif
fab
portion
cell
express
larg
number
thousand
one
million
per
fcrexpress
cell
respond
simultan
multitud
antigen
highaffin
fcr
bind
monomer
immunoglobulin
absenc
antigen
ie
immun
complex
fig
proport
highaffin
fcr
may
therefor
occupi
vivo
antibodi
howev
may
dissoci
highaffin
fcr
make
receptor
avail
bind
antibodi
dissoci
constant
highaffin
fcr
therefor
critic
determin
avail
antibodi
present
environ
exemplifi
murin
highaffin
receptor
k
found
receptor
also
lowaffin
receptor
ige
ka
wonder
whether
properti
biolog
meaning
one
inde
expect
satur
vivo
thu
unavail
ige
found
half
life
minut
ige
immun
complex
perfectli
replac
presenc
normal
serum
mancardi
et
al
contrari
extrem
high
affin
constant
ka
highaffin
receptor
ige
express
mast
cell
basophil
mice
human
due
extrem
low
dissoci
constant
kulczycki
metzger
consequ
ige
antibodi
remain
bound
extend
period
time
spite
extrem
low
plasma
concentr
affin
lowaffin
fcr
bruhn
et
al
low
enabl
bind
monomer
antibodi
howev
bind
antibodi
multival
immun
complex
high
avid
fig
consequ
absenc
antigen
lowaffin
fcr
eg
remain
free
spite
high
concentr
circul
immunoglobulin
eg
igg
therefor
avail
immun
complex
whenev
come
close
enough
immun
complex
bind
lowaffin
fcrexpress
cell
antibodi
concentr
multival
antigen
immun
complex
mani
antibodi
bind
time
mani
fcr
cell
membran
bound
fcr
immun
complex
remain
lowaffin
fcrexpress
cell
antibodi
dissoci
individu
fcr
rapidli
replac
antibodi
present
complex
antibodi
dissoci
fcr
remain
bound
antigen
also
engag
fcr
previous
engag
interact
immun
complex
lowaffin
fcr
therefor
time
labil
stabl
highli
dynam
lowaffin
fcr
interact
immun
complex
concentr
composit
immun
complex
therefor
determin
avid
bind
receptor
inde
matter
bind
local
concentr
fc
portion
concentr
depend
densiti
epitop
present
antigen
molecul
recogn
antibodi
involv
immun
complex
antibodi
specif
therefor
bind
differ
avid
fcr
complex
antigen
high
densiti
specif
epitop
complex
antigen
low
densiti
epitop
fig
interest
situat
interact
fcr
antibodi
cell
surfac
antigen
possibl
target
cell
may
express
fcr
rare
consid
antibodi
therefor
view
bind
tran
target
cell
antigen
via
fab
portion
effector
cell
fcr
via
fc
portion
target
cell
express
fcr
antibodi
bind
ci
ie
target
antigen
via
fab
portion
fcr
via
fc
portion
cell
fig
bind
antigen
locat
membran
fcr
markedli
enhanc
local
concentr
antibodi
concentr
plane
rather
dispers
volum
bind
fcr
also
enhanc
local
concentr
ie
densiti
specif
epitop
cell
membran
fcfcr
ci
bind
demonstr
trigger
mast
cell
activ
use
alloantibodi
mhc
class
antigen
express
cell
et
al
voisin
extens
use
inhibit
b
cell
activ
use
antiimmunoglobulin
igg
antibodi
phillip
parker
one
expect
ci
bind
appli
mani
monoclon
antibodi
use
passiv
immunotherapi
affin
immunoglobulin
bind
fcr
depend
glycosyl
fc
portion
arnold
et
al
thu
heavi
chain
contain
singl
coval
attach
biantennari
nglycan
highli
conserv
residu
domain
point
mutat
glycosyl
site
abrog
abil
igg
antibodi
bind
engin
mutat
eg
aglycosyl
antibodi
therefor
longer
engag
use
blockingonli
molecul
veri
et
al
notic
mutat
affect
bind
igg
neonat
fcr
fcrn
protect
igg
degrad
ka
variou
mous
human
fcr
span
least
five
log
highaffin
fcr
defin
oper
abil
bind
monomer
immunoglobulin
ka
rang
lowaffin
fcr
defin
unabl
bind
monomer
immunoglobulin
abl
bind
immun
complex
ka
rang
bruhn
et
al
fcr
appear
specif
one
class
subclass
immunoglobulin
mous
bind
mous
likewis
human
bind
four
subclass
human
igg
howev
affin
three
receptor
much
lower
lower
extent
notic
human
lower
affin
four
subclass
human
igg
bruhn
et
al
pigr
bind
dimer
iga
pentamer
igm
bako
et
al
highaffin
receptor
mous
lowaffin
receptor
mous
ige
mancardi
et
al
likewis
murin
lowaffin
receptor
mous
igg
found
bind
also
mous
ige
takizawa
et
al
wherea
affin
receptor
mous
affin
mous
ige
order
mancardi
et
al
extrem
low
affin
limit
nonspecif
pose
question
specif
fcr
discuss
fcr
display
gradient
affin
variou
isotyp
immunoglobulin
gradient
extrem
wide
seem
continu
specif
fcr
immunoglobulin
class
subclass
therefor
appear
quantit
qualit
determin
specif
fcr
larg
enough
differ
affin
differ
immunoglobulin
classic
fcr
structur
similar
bcr
tcr
vast
major
made
noncoval
associ
subunit
ligandbind
subunit
affin
variou
class
subclass
immunoglobulin
one
two
itamcontain
signal
subunit
share
multisubunit
fcr
fig
altogeth
form
famili
polypeptid
extracellular
immunoglobulinbind
domain
secondari
structur
typic
immunoglobulin
superfamili
igsf
molecul
hydrophob
transmembran
domain
nonstructur
intracytoplasm
domain
variabl
length
differ
extracellular
domain
core
structur
receptor
iga
igg
fcrn
ige
hulett
hogarth
bind
involv
hing
two
juxtamembran
extracellular
domain
fcr
penultim
constant
domain
immunoglobulin
heavi
chain
fcrn
uniqu
mhc
class
ilik
molecul
bind
fc
portion
igg
high
affin
burmeist
et
al
wide
express
homodim
made
two
disulfid
bondlink
polypeptid
highli
conserv
mice
human
orloff
et
al
share
activ
multichain
fcr
domain
polypeptid
associ
multichain
fcr
express
mast
cell
basophil
kinet
et
al
multichain
fcr
must
associ
least
one
specif
subunit
order
express
need
lobel
et
al
takai
et
al
letourneur
et
al
express
receptor
therefor
depend
tissu
distribut
mice
activ
fcr
takai
et
al
mous
human
also
need
associ
kinet
express
mast
cell
basophil
speci
express
restrict
cell
mice
kinet
et
al
human
gounni
et
al
joseph
et
al
fcrn
associ
anoth
itamcontain
subunit
microblobulin
associ
mandatori
fcrn
express
israel
et
al
fcr
singlechain
receptor
human
mice
human
two
extracellular
domain
bind
igg
low
affin
human
extracellular
domain
intracytoplasm
domain
ravetch
kinet
contain
one
itam
wherea
contain
one
itim
itamcontain
singlechain
fcr
howev
report
form
homodim
constitut
cell
membran
without
deliv
activ
signal
absenc
ligand
powel
et
al
glycosylphosphatidylinositolanchor
singlechain
fcr
uniqu
human
bind
human
igg
low
affin
fcr
polymer
immunoglobulin
pigr
extracellular
domain
bind
dimer
iga
pentamer
igm
known
associ
itamcontain
subunit
fcr
associ
belong
igsf
ctype
lectin
superfamili
fcr
bind
ige
conrad
bind
howev
involv
interact
sugar
residu
abund
fc
portion
ige
extracellular
lectin
domain
affin
ige
rel
low
howev
express
homotrim
bind
ige
immun
complex
high
avid
kilmon
et
al
known
associ
signal
subunit
like
bcr
tcr
fcr
aggreg
plurival
ligand
unlik
bcr
tcr
howev
fcr
form
heteroaggreg
bcr
tcr
singl
specif
express
b
cell
form
homoaggreg
engag
nake
antigen
peptidemch
complex
respect
fcr
also
form
homoaggreg
engag
immun
complex
made
monoclon
antibodi
singl
specif
commonli
use
laboratori
engag
fcr
condit
instrument
establish
bind
paramet
fcr
elucid
mechan
signal
transduct
use
fcr
experiment
situat
howev
artifact
immun
respons
inde
polyclon
also
pluriisotyp
immun
procedur
induc
singl
class
antibodi
depend
concentr
antigen
depend
adjuv
depend
rout
immun
isotyp
antibodi
favor
case
overal
isotyp
pattern
respons
markedli
alter
even
immun
mice
protocol
promot
strong
respons
one
inject
high
concentr
protein
freund
complet
adjuv
follow
repeat
inject
high
dose
antigen
incomplet
freund
adjuv
antibodi
remain
far
domin
isotyp
antibodi
detect
level
ige
antibodi
even
observ
serum
jonsson
et
al
consequ
immun
complex
form
vivo
contain
antibodi
sever
class
subclass
fcr
differ
specif
coexpress
fcrexpess
cell
pluriisotyp
immun
complex
engag
sever
type
fcr
cell
membran
aggreg
physiolog
condit
fcr
form
heteroaggreg
composit
fcr
heteroaggreg
depend
multipl
paramet
depend
fcr
express
given
cell
given
time
given
place
depend
respect
local
concentr
antibodi
differ
isotyp
depend
natur
concentr
antigen
present
environ
fig
fcr
heteroaggreg
differ
composit
may
markedli
differ
signal
properti
itamcontain
fcr
gener
activ
signal
fcr
human
neutrophil
eosinophil
monocyt
contain
two
itam
fcr
associ
mast
cell
basophil
contain
three
itam
contain
one
itam
howev
contain
two
itam
dimer
powel
et
al
signific
presenc
sever
itam
immunoreceptor
unknown
one
itam
enough
aggreg
singlechain
chimer
molecul
intracytoplasm
domain
activ
transfect
cell
express
et
al
although
trigger
differ
signal
b
cell
choquet
et
al
upon
receptor
aggreg
itam
phosphoryl
src
famili
tyrosin
kinas
intracellular
chemic
perturb
initi
constitut
dynam
intracellular
signalosom
activ
signal
gener
signalosom
build
tyrosinerich
transmembran
adapt
protein
resid
constitut
lipidrich
membran
microdomain
bezman
koretzki
signal
propag
intracellularli
via
variou
metabol
pathway
altogeth
lead
gene
transcript
activ
lipid
metabol
membran
alter
associ
exocytosi
itamcontain
fcr
also
gener
inhibit
signal
inhibit
signal
gener
activ
fcr
readili
observ
challeng
mast
cell
sensit
ige
antibodi
increas
concentr
specif
antigen
mast
cell
degranul
dosedepend
increas
maximum
degranul
thereaft
decreas
rapidli
background
level
inhibit
excess
antigen
long
interpret
result
reduc
abil
antigen
aggreg
effici
wofsi
et
al
induc
phosphoryl
intracellular
protein
howev
keep
increas
beyond
optim
concentr
antigen
moreov
inhibit
excess
antigen
abrog
mast
cell
mice
defici
domaincontain
inositol
phosphatas
gimborn
et
al
final
mast
cell
mice
display
enhanc
degranul
respons
optim
suboptim
antigen
concentr
huber
et
al
therefor
gener
inhibit
signal
suboptim
optim
aggreg
supraoptim
aggreg
antigen
similar
effect
defici
observ
activ
fcr
nakamura
et
al
itamcontain
fcr
therefor
gener
mixtur
activ
inhibit
signal
malbec
et
al
activ
signal
domin
inhibit
signal
physiolog
condit
itimcontain
fcr
itim
present
intracytoplasm
domain
murin
human
isoform
et
al
tyrosylphosphoryl
trigger
intracellular
signal
aggreg
trigger
neg
signal
coaggreg
activ
receptor
immun
complex
et
al
condit
itim
phosphoryl
srcfamili
tyrosin
kinas
phosphoryl
itam
activ
receptor
malbec
et
al
domain
high
affin
phosphoryl
itim
bruhn
et
al
larg
amount
recruit
brought
signalosom
gener
activ
fcr
lesourn
et
al
therefor
potenti
neg
signal
gener
itamcontain
fcr
lesourn
et
al
inhibit
signal
becom
domin
activ
signal
neg
regul
itamcontain
fcr
one
exampl
heteroaggreg
critic
affect
fcr
signal
wide
occur
situat
heteroaggreg
whether
coaggreg
differ
type
fcr
coaggreg
fcr
immunoreceptor
actual
rule
rather
except
physiolog
condit
heteroaggreg
involv
activ
fcr
happen
pluriisotyp
immun
complex
engag
fcr
differ
immunoglobulin
class
cell
express
correspond
itamcontain
fcr
one
exempl
human
skin
mast
cell
sensit
ige
antibodi
expos
immun
complex
contain
igg
antibodi
antigen
due
high
concentr
igg
antibodi
allergen
like
complex
igg
reach
ige
tissu
mast
cell
human
skin
mast
cell
express
zhao
et
al
result
coengag
human
mast
cell
activ
signal
ident
signal
gener
receptor
contain
differ
itam
type
signal
expect
integr
lead
cell
respons
may
differ
signal
gener
alon
heteroaggreg
involv
inhibitori
fcr
activ
fcr
ident
differ
specif
immunoglobulin
one
exampl
heteroaggreg
fcr
ident
specif
human
mous
basophil
challeng
igg
immun
complex
basophil
speci
coexpress
itamcontain
itimcontain
receptor
igg
human
basophil
express
wherea
mous
basophil
express
basophil
speci
howev
fail
activ
igg
immun
complex
reason
inhibit
domin
activ
cell
cassard
et
al
exampl
heteroaggreg
fcr
differ
specif
cell
sensit
ige
challeng
igg
immun
complex
condit
igg
immun
complex
coaggreg
itam
itimcontain
also
itamcontain
cell
respons
neg
regul
cassard
et
al
igg
antibodi
therefor
control
igemedi
human
mous
basophil
activ
heteroaggreg
involv
fcr
nonfcr
immunoreceptor
instanc
cell
express
one
type
fcr
immun
complex
coengag
fcr
whether
inhibitori
b
cell
activ
nk
cell
immunoreceptor
whether
activ
bcr
b
cell
inhibitori
killer
cell
inhibitori
receptor
long
intracytoplams
domain
kirl
nk
cell
consequ
bcr
signal
neg
regul
b
cell
phillip
parker
amigorena
et
al
signal
neg
regul
kirl
nk
cell
moretta
et
al
consid
fcr
signal
appear
exquisit
suscept
control
andor
control
fcr
andor
immunoreceptor
coengag
fcr
superstructur
immun
complex
ensu
biolog
respons
may
therefor
tightli
control
function
antibodi
antigen
present
environ
superstructur
buildup
cell
membran
depend
fcr
avail
immun
complex
cell
membran
ie
tissu
distribut
fcr
cell
hematopoiet
origin
express
combin
fcr
typic
cell
type
fig
fcr
essenti
express
myeloid
cell
type
express
lymphoid
cell
b
cell
nk
cell
nkt
cell
like
possibl
innat
lymphoid
cell
ilc
express
fcr
ilc
express
fcr
report
yet
nonhematopoiet
cell
endotheli
cell
tumor
cell
cassard
et
al
also
express
fcr
fcrn
express
mani
cell
includ
epitheli
cell
monocyt
macrophag
dendrit
cell
neutrophil
hepatocyt
gheti
ward
activ
fcr
express
myeloid
cell
lymphoid
cell
classic
antigen
receptor
ie
nk
cell
perussia
et
al
intraepitheli
cell
intestin
deusch
et
al
sandor
et
al
woodward
jenkinson
express
matur
b
lymphocyt
lymphocyt
therefor
express
one
type
antigen
receptor
activ
fcr
interfer
lymphocyt
activ
trigger
clonal
express
antigen
receptor
low
level
howev
found
subset
murin
cell
effici
trigger
antibodydepend
cellmedi
cytotox
dhanji
et
al
express
myeloid
cell
b
lymphocyt
nk
cell
cell
express
express
sever
inhibitori
receptor
involv
cellcel
interact
long
restrict
tissu
distribut
human
mice
cell
express
one
type
fcr
b
cell
express
mice
human
nk
cell
typic
express
mice
human
snp
gene
howev
determin
express
nk
cell
human
donor
van
der
heijden
et
al
cell
express
sever
fcr
express
igg
receptor
human
iga
receptor
monocytemacrophag
express
type
hematopiet
cell
express
human
cell
monocyt
express
higher
level
blood
leukocyt
basophil
express
much
higher
level
blood
cell
includ
b
cell
cassard
et
al
wide
tissu
distribut
fcr
endow
antibodi
wide
spectrum
biolog
properti
depend
function
repertoir
fcrexpress
cell
cell
type
endocytos
phagocytos
even
less
transcytos
mani
cell
express
fcrn
pinocytos
releas
igg
molecul
bound
fcrn
intracellularli
therebi
protect
lysosom
degrad
cell
expel
granul
contain
cytotox
mediat
cell
granul
contain
vasoact
proinflammatori
mediat
proteas
mani
cell
synthes
cytokin
chemokin
growth
factor
differ
type
fcr
therefor
involv
varieti
biolog
function
includ
pathogen
clearanc
toxin
neutral
antigen
captur
initi
antigen
present
cytotox
inflammatori
respons
due
differenti
tissu
distribut
fcr
antibodi
select
fcrexpress
cell
involv
biolog
respons
fcr
therefor
determin
cell
engag
specif
class
subclass
antibodi
discuss
outcom
depend
function
repertoir
cell
exemplifi
analysi
cell
type
involv
system
anaphylaxi
igeinduc
passiv
system
anaphylaxi
psa
abrog
mice
dombrowicz
et
al
mast
celldefici
mice
kalesnikoff
galli
feyerabend
et
al
histidin
decarboxylasedefici
mice
makabekobayashi
et
al
histamin
releas
mast
cell
trigger
aggreg
upon
bind
antigen
receptorbound
ige
becam
paradigmat
model
anaphylaxi
wide
accept
interpret
forgot
igginduc
passiv
anaphylaxi
describ
zoltan
ovari
ovari
b
ige
antibodi
discov
ishizaka
et
al
psa
later
shown
depend
miyajima
et
al
respons
cell
howev
still
remain
unidentifi
reaction
abrog
mast
cell
miyajima
et
al
basophil
defici
mice
ohnmacht
et
al
recent
found
mice
lack
develop
activ
system
anaphylaxi
asa
sever
wildtyp
mice
immun
antigen
complet
freund
adjuv
challeng
antigen
intraven
likewis
use
quintupl
fcrdefici
mice
express
one
activ
fcr
highaffin
receptor
express
monocytemacrophag
neutrophil
unravel
unexpect
role
neutrophil
asa
jonsson
et
al
reason
explain
seemingli
discrep
find
class
subclass
antibodi
select
cell
type
fig
ige
engag
cell
ie
mast
cell
basophil
mice
wherea
engag
cell
ie
monocytemacrophag
andor
neutrophil
engag
mani
cell
express
immun
respons
pluriisotyp
cell
differ
type
share
receptor
isotyp
antibodi
select
heterogen
cell
popul
rather
homogen
singlecel
popul
complex
antigen
popul
consist
mixtur
variou
fcrexpress
cell
either
present
recruit
chemokin
andor
prolifer
respons
growth
factor
site
reaction
biolog
process
fcr
involv
therefor
result
respons
mani
cell
engag
reaction
given
place
given
time
one
keep
consid
asa
exampl
cell
type
individu
found
contribut
reaction
present
togeth
blood
stream
antibodi
circul
challeng
antigen
inject
rel
contribut
cell
therefor
depend
rel
concentr
differ
class
subclass
antibodi
fcr
express
cell
interplay
fcr
domin
isotyp
antibodi
follow
immun
antigen
freund
adjuv
activ
fcr
affin
mous
mast
cell
malbec
et
al
basophil
cassard
et
al
express
mast
cell
expect
numer
blood
basophil
expect
play
critic
role
either
express
high
level
prevent
basophil
activ
cassard
et
al
cell
express
neutrophil
monocytemacrophag
much
less
abund
activ
receptor
affin
psa
observ
mice
express
neutrophil
demonstr
contribut
shock
jonsson
et
al
ige
five
hundr
thousand
one
millionfold
less
abund
antibodi
bind
primarili
also
igeinduc
psa
abrog
mice
unlik
contribut
part
asa
depend
ige
mast
cell
basophil
remain
like
candid
data
altogeth
indic
ige
induc
anaphylaxi
engag
mast
cell
basophil
neutrophil
respect
select
deplet
experi
wildtyp
mice
could
clarifi
respect
role
cell
asa
neutrophil
deplet
markedli
reduc
asa
wildtyp
mice
basophil
deplet
result
milder
signific
reduct
deplet
basophil
neutrophil
virtual
abrog
reaction
notic
asa
could
induc
mast
celldefici
mice
confirm
expect
insignific
contribut
cell
asa
neutrophil
lower
extent
basophil
therefor
main
effector
asa
neutrophil
involv
via
lower
extend
via
basophil
involv
via
ige
antibodi
potent
adjuv
spite
low
plasma
concentr
ige
antibodi
enhanc
antigen
present
b
cell
ige
immun
complex
inde
engag
b
cell
lead
effici
antigen
present
cell
getahun
et
al
hjelm
et
al
result
ige
antibodi
enhanc
product
class
antibodi
igg
antibodi
also
behav
adjuv
uptak
antigenigg
antibodi
complex
dendrit
cell
via
activ
consequ
mhc
class
ii
present
heyman
mhc
class
cross
present
machi
et
al
enhanc
expectedli
activ
present
antigenantibodi
complex
counterbalanc
express
dendrit
cell
kalergi
ravetch
howev
promot
antigen
present
b
cell
follicular
dendrit
cell
mond
et
al
express
cell
inde
engag
fc
portion
immun
complex
prevent
coengag
bcr
b
cell
el
shikh
et
al
antigen
immun
complex
bound
onto
follicular
dendrit
cell
thu
potent
induc
antibodi
respons
free
antigen
whether
vitro
tew
et
al
vivo
wu
et
al
el
shikh
et
al
unlik
immun
respons
solubl
antigen
markedli
enhanc
igg
antibodi
immun
respons
particul
antigen
well
known
suppress
igg
antibodi
minut
amount
specif
igg
inde
suppress
antiheterolog
erythrocyt
immun
respons
whether
primari
secondari
observ
first
made
henri
jern
rational
inject
mother
given
birth
rh
babi
antirhd
antibodi
prevent
treatment
hemolyt
diseas
newborn
fcrdefici
mice
becam
avail
unexpectedli
found
neg
regul
account
feedback
regul
antibodi
regul
unalt
mice
heyman
et
al
also
mice
lack
karlsson
et
al
mechan
behind
inhibit
remain
unclear
antivir
antibodi
may
profoundli
affect
viral
infect
fcrdepend
mechan
recent
report
neutral
effect
antibodi
depend
interact
fc
portion
uniqu
intracellular
fcr
name
subsequ
degrad
virusantibodi
complex
proteasom
malleri
et
al
classic
activ
fcr
also
need
clear
influenza
viru
huber
et
al
notic
engag
activ
unrel
immun
complex
found
inhibit
replic
primari
human
macrophag
david
et
al
rather
protect
antibodi
favor
aggrav
viral
infect
antispik
antibodi
viral
protein
enabl
sever
acut
respiratori
syndrom
sra
coronaviru
infect
epitheli
cell
prevent
cell
infect
antispik
antibodi
howev
enabl
infect
human
immun
cell
interact
jaum
et
al
likewis
antibodi
may
enhanc
hiv
infect
antibodi
complex
protein
hiv
inde
bind
fust
receptor
aggreg
ensu
enabl
intern
antibodyhiv
complex
consequ
monocyt
infect
jouault
et
al
interestingli
fcr
may
promot
viral
infect
induc
antibodyindepend
immunosuppress
nucleoplasmid
protein
measl
viru
inde
found
bind
murin
human
bind
found
inhibit
antibodi
product
human
b
cell
mechan
propos
account
wellknown
immunosuppress
associ
measl
infect
ravanel
et
al
specif
antibodi
well
known
neutral
bacteri
toxin
unexpectedli
neutral
b
anthaci
toxin
recent
found
depend
engag
fcr
abboud
et
al
fcr
involv
antibodydepend
clearanc
bacteria
legionella
joller
et
al
salmonella
tobar
et
al
toxoplasma
joiner
et
al
phagocytosi
mice
fail
control
leishmania
major
padigel
farrel
mycobacterium
tuberculosi
maglion
et
al
infect
wherea
mice
display
enhanc
resist
bacteria
seem
play
predomin
role
protect
thoma
buxbaum
may
contribut
protect
bordello
pertussi
infect
ioanfacsinay
et
al
like
measl
viru
bacteria
bind
fcr
express
immun
cell
even
complex
antibodi
interact
facilit
infect
escherichia
coli
express
outer
membran
protein
ompa
bind
macrophag
bind
two
consequ
facilit
entri
bacteria
cell
prevent
phosphoryl
mittal
et
al
mice
resist
e
coli
infect
ige
antibodi
wellknown
induc
allerg
reaction
engag
express
mast
cell
basophil
experiment
anim
human
patient
dombrowicz
et
al
wershil
et
al
arimura
et
al
fungleung
et
al
one
intrigu
question
mast
cell
basophil
account
igemedi
psa
respons
mast
cell
locat
contribut
allerg
symptom
express
eosinophil
tanaka
et
al
monocyt
maurer
et
al
alveolar
macrophag
ochiai
et
al
neutrophil
gounni
et
al
platelet
joseph
et
al
patient
high
ige
level
expect
differ
allergi
affect
differ
tissu
remain
delin
unlik
wellestablish
role
experiment
anaphylaxi
role
human
allergi
far
clear
abil
human
induc
allerg
reaction
demonstr
use
transgen
mice
jonsson
et
al
mancardi
et
al
human
trigger
igginduc
psa
asa
express
mast
cell
also
respons
igginduc
pca
human
skin
mast
cell
express
zhao
et
al
interestingli
mous
defici
endogen
transgen
human
underw
anaphylaxi
follow
inject
aggreg
human
igg
smith
et
al
type
cell
express
especi
ratio
decis
influenc
outcom
ratio
high
human
neutrophil
cell
respond
robustli
igg
immun
complex
accord
vitro
observ
transfert
human
neutrophil
restor
anaphylaxi
mice
jonsson
et
al
ratio
low
human
basophil
cell
respond
immun
complex
igg
receptor
express
human
basophil
inde
function
inhibitor
cell
activ
igg
immun
complex
coengag
basophil
inhibit
igedepend
basophil
activ
normal
donor
test
cassard
et
al
autoimun
diseas
depend
autoantibodi
involv
unbal
activ
inhibitori
fcr
activ
fcr
account
clinic
express
autoimun
sever
murin
model
mice
protect
multipl
sclerosi
robbieryan
et
al
develop
antiplateletinduc
thrombocytopen
purpura
fossatijimack
et
al
display
less
lesion
model
parkinson
diseas
et
al
nimmerjahn
ravetch
fossatijimack
et
al
nimmerjahn
et
al
found
contribut
platelet
deplet
system
lupu
erythematosu
sere
et
al
experiment
hemolyt
anemia
meyer
et
al
sy
et
al
glomerulonephr
fujii
et
al
arthriti
ioanfacsinay
et
al
bruhn
et
al
mancardi
et
al
autoantibodi
induc
thrombocytopen
purpura
reilli
et
al
arthriti
pietersz
et
al
transgen
mice
express
human
express
human
mice
restor
joint
inflamm
kbxn
model
rheumatoid
arthriti
mancardi
et
al
autoantibodi
myelin
found
multipl
sclerosi
autaoantibodi
dopaminerg
neuron
found
parkinson
diseas
mcraedegueurc
et
al
thought
induc
inflamm
activ
fcrexpress
phagocyt
cell
mani
cell
central
nervou
system
express
fcr
immun
cell
recruit
bloodstream
brain
disord
convers
prevent
autoimmun
mice
spontan
develop
autoimmun
diseas
age
antidna
antichromatin
antibodi
die
glomerulonephr
ravetch
bolland
importantli
partial
restor
level
b
cell
lupuspron
mous
strain
suffici
restor
toler
prevent
diseas
suggest
minor
alter
express
may
suffici
induc
autoimmun
mcgaha
et
al
mackay
et
al
polymorph
transmembran
domain
human
found
decreas
abil
transloc
lipd
raft
inhibit
bcr
signal
kono
et
al
antitumor
antibodi
lead
signific
reduct
tumor
mass
inject
wt
mice
nimmerjahn
ravetch
mice
clyne
et
al
albanesi
et
al
also
bevaart
et
al
nimmerjahn
ravetch
report
particip
reaction
antitumor
effect
antitumor
antibodi
markedli
enhanc
mice
clyne
et
al
antibodydepend
cellmedi
cytotox
thought
account
vivo
effect
koen
et
al
discuss
provid
ground
passiv
immunotherapi
cancer
natur
effector
cell
unclear
celldeplet
experi
suggest
role
monocytesmacrophag
otten
et
al
possibl
myeloid
cell
besid
nk
cell
antitumor
antibodi
opposit
effect
enhanc
tumor
growth
intraven
inject
antibodi
antigen
express
tumor
cell
inde
prevent
reject
allogen
tumor
cell
inject
subcutan
lead
death
mice
otherwis
clear
tumor
within
week
voisin
spite
extens
investig
mechan
long
known
enhanc
phenomenon
kaliss
remain
larg
unknown
recent
found
enhanc
abrog
mice
getahun
et
al
unpublish
antibodi
appear
potent
effector
molecul
howev
magic
bullet
sometim
view
refer
paul
ehrlich
chemic
compound
select
affin
pathogen
strebhardt
ullrich
discuss
review
action
subtl
engag
multipl
receptor
adapt
structur
signal
varieti
cell
adapt
function
respons
enabl
immun
respons
adapt
infinit
varit
antigen
stimul
take
account
complex
interact
antigen
antibodi
fcr
cell
occur
bodi
excit
challeng
becom
requir
understand
pathogenesi
diseas
develop
new
therapeut
tool
one
inde
exploit
complex
amelior
immunotherapi
conceiv
new
antibodydepend
approach
varieti
diseas
variou
immun
diseas
symptom
local
manifest
system
process
allergi
autoimmun
disord
antigen
either
appli
present
local
exampl
diseas
develop
intersect
plural
system
effector
plural
tissu
effector
may
also
appli
local
tissuespecif
infect
symptom
primarili
due
antipathogen
immun
respons
thu
one
take
exampl
allergi
clinic
manifest
cutan
allergi
respiratori
allergi
depend
effector
cell
present
skin
respiratori
tract
respect
target
organ
respond
ident
inflammatori
mediat
secret
effector
cell
better
understand
polymorph
allergi
mean
better
treat
antibodi
molecul
express
target
cell
increasingli
use
passiv
immunotherapi
aim
engag
fcr
induc
phagocytosi
andor
adcc
fcrexpress
effector
cell
destroy
target
cell
thu
antibodi
rituximab
use
kill
transform
b
cell
manch
et
al
b
cell
respons
product
pathogen
autoantibodi
rheumatoid
arthriti
shaw
et
al
edward
et
al
bind
trastuzumab
inhibit
prolifer
breast
ovari
lung
cancer
cell
prevent
receptor
dimer
yake
et
al
also
induc
tumor
destruct
engag
activ
fcr
cytotox
cell
clyne
et
al
antibodi
molecul
express
dendrit
cell
also
enhanc
antigen
present
consequ
tcell
depend
cytotox
tumor
cell
unexpectedli
effect
found
involv
li
ravetch
inde
bind
tran
cell
fc
portion
antitnf
receptor
antibodi
mimic
effect
multimer
ligand
aggreg
tnf
receptor
much
effici
li
ravetch
likewis
therapeut
effect
omalizumab
monoclon
antibodi
direct
site
ige
develop
prevent
mast
cell
basophil
sensit
ige
allerg
patient
happen
mediat
unanticip
mechan
omalizumab
inde
form
igeantiig
complex
rapidli
degrad
probabl
intern
result
serum
ige
becom
undetect
djukanov
et
al
halflif
decreas
occupi
ige
basophil
mast
cell
markedli
reduc
express
efficaci
therapeut
antibodi
establish
one
aim
enhanc
want
effect
decreas
unwant
effect
situat
simpler
activ
immun
respons
therapeut
antibodi
direct
singl
epitop
monoisotyp
human
antibodi
made
graft
antigenspecif
variabl
sequenc
onto
human
backbon
constant
domain
wellknow
human
mani
case
thu
one
engin
therapeut
antibodi
specif
properti
one
mutat
main
glycosyl
site
eg
introduc
point
mutat
fc
portion
gener
antibodi
bind
target
antigen
without
engag
fcr
except
fcrn
preserv
half
life
veri
et
al
one
increas
half
life
antibodi
gener
mutat
enhanc
affin
fc
portion
fcrn
ward
ober
consequ
plasma
concentr
therapeut
antibodi
increas
dall
acqua
et
al
one
either
chang
glycosyl
gener
mutat
enhanc
affin
antibodi
activ
fcr
thu
mutat
remov
fucos
residu
fc
portion
antibodi
enhanc
affin
human
natsum
et
al
niwa
et
al
convers
one
gener
antibodi
mutat
fc
portion
enhanc
affin
antibodi
inhibitori
fcr
thu
antihuman
antibodi
bind
sever
hundredfold
higher
affin
nonmut
antibodi
suppress
bcrdepend
activ
b
cell
healthi
donor
sle
patient
reduc
serum
igm
igg
ige
level
scid
mice
engraft
sle
pbmc
increas
surviv
mice
engraft
pbmc
sle
patient
horton
et
al
likewis
antiig
antibodi
fc
portion
increas
affin
reduc
free
total
ige
level
prevent
gener
igesecret
plasma
cell
chu
et
al
step
forward
may
know
cell
type
fcr
engag
given
antibodi
depend
locat
target
cell
molecul
use
therapeut
antibodi
preferenti
engag
desir
fcr
appropri
effector
cell
phenotyp
fcr
effector
cell
individu
patient
assess
abil
activ
cell
would
inde
progress
toward
person
medicin
gener
new
vaccin
remain
major
challeng
immunologist
antibodi
respons
protect
effect
overwhelm
major
vaccin
neutral
antibodi
keep
thought
account
protect
case
fcrdepend
mechan
ignor
differ
strategi
may
necessari
vaccin
system
infect
local
infect
also
exemplifi
antisar
coronaviru
antibodi
one
want
prevent
antibodi
enabl
viru
infect
fcrexpress
cell
infect
absenc
antibodi
jaum
et
al
protect
anticanc
vaccin
avail
yet
effort
made
induc
andor
amplifi
cellmedi
cytotox
tumor
cell
efficaci
passiv
administ
therapeut
antitumor
antibodi
howev
suggest
vaccin
would
gener
antibodi
may
use
know
induc
antibodi
therapeut
benefit
antibodi
tumor
enhanc
properti
requir
mechan
antibodydepend
enhanc
understood
final
discuss
antibodi
exert
whole
array
biolog
effect
one
may
stop
think
vaccin
mean
kill
destroy
remov
unwant
molecul
cell
pathogen
recent
found
coengag
growth
factor
receptor
could
inhibit
prolifer
transform
tumor
cell
malbec
basi
observ
vaccin
could
aim
coengag
varieti
target
antigen
inhibitori
receptor
interfer
pathogen
process
due
cell
activ
prolifer
would
extend
field
applic
vaccin
diseas
infecti
diseas
cancer
inflammatori
diseas
specif
immunotherapi
allergi
exampl
propos
one
centuri
ago
use
sinc
efficaci
indic
howev
remain
limit
might
markedli
enhanc
mechan
behind
empir
maneuv
better
known
exploit
